The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study

Lisdexamfetamine dimesylate (LDX) is the only drug currently approved by the FDA for the treatment of Binge-Eating Disorder (BED), but little is known about the behavioural mechanisms that underpin the efficacy of LDX in treating BED. We examined the behavioural and neural effects of an acute dose o...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Elizabeth, Martin, Elizabeth, Rotshtein, Pia, Qureshi, Kasim L., Chamberlain, Samuel R., Spetter, Maartje S., Dourish, Colin T., Higgs, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744047/
https://www.ncbi.nlm.nih.gov/pubmed/35013131
http://dx.doi.org/10.1038/s41398-021-01770-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744047/
https://www.ncbi.nlm.nih.gov/pubmed/35013131
http://dx.doi.org/10.1038/s41398-021-01770-4

Ejemplares similares